CG Oncology, Inc.
CGON- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001991792
In the last 90 days, CG Oncology, Inc. insiders filed 0 open-market purchases and 4 sales; 227 institutions reported holding it in 13F filings for Q2 2026, worth $6.66B in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in CG Oncology, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 111
- +15 vs. Q1 2024
- Shares held
- 43.3M
- +4.50M (+11.6%) vs. Q1 2024
- Total value
- $1.37B
- −$335.9M (−19.7%) vs. Q1 2024
- New holders
- 32
- 46 more added
- Sold out
- 17
- 17 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CGON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 227 | $6.66B |
| Q1 2026 | 233 | $6.03B |
| Q4 2025 | 195 | $3.43B |
| Q3 2025 | 176 | $3.13B |
| Q2 2025 | 163 | $1.97B |
| Q1 2025 | 142 | $1.74B |
| Q4 2024 | 140 | $1.90B |
| Q3 2024 | 121 | $1.96B |
| Q2 2024 | 111 | $1.37B |
| Q1 2024 | 96 | $1.70B |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding CG Oncology, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Avidity Partners Management LP | 1,296,225 | $40.9M | 1.74% | −158,540−10.9% | Reduced |
| RTW Investments, LP | 1,344,074 | $42.4M | 0.66% | +930,404+224.9% | Added |
| Ra Capital Management, L.P. | 1,397,433 | $44.1M | 0.58% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 1,427,017 | $45.0M | 0.02% | −94,415−6.2% | Reduced |
| Fan Yu | 1,578,344 | $49.8M | 65.11% | +1,578,344 | New |
| BlackRock Inc. | 1,976,070 | $62.4M | 0.00% | −542,480−21.5% | Reduced |
| Vanguard Group Inc | 2,244,121 | $70.8M | 0.00% | +19,103+0.9% | Added |
| BVF Inc | 2,417,885 | $76.3M | 2.14% | +533,694+28.3% | Added |
| Braidwell LP | 3,309,507 | $104.5M | 3.28% | +2,179,272+192.8% | Added |
| TCG Crossover Management, LLC | 3,670,206 | $115.9M | 12.08% | +100,000+2.8% | Added |
| Decheng Capital LLC | 5,458,810 | $172.3M | 52.81% | 00.0% | Unchanged |
| Holocene Advisors, LP | 0 | $0 | 0.00% | −766,625−100.0% | Sold out |
| VR Adviser, LLC | 0 | $0 | 0.00% | −350,000−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −306,226−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −300,000−100.0% | Sold out |
| Rock Springs Capital Management LP | 0 | $0 | 0.00% | −170,859−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −125,000−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −40,723−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −28,672−100.0% | Sold out |
| Blackstone Group Inc. | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −24,807−100.0% | Sold out |
| Gilder Gagnon Howe & Co LLC | 0 | $0 | 0.00% | −18,523−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −18,354−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −11,149−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −5,728−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −4,800−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −4,100−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −1,246−100.0% | Sold out |